Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Novo Nordisk has recently completed a clinical study titled ...

Diabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition agreement with Prothena focusing on drugs for ATTR amyloidosis. The Danish drugmaker is paying ...

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ... and anti-amyloid therapy PRX004 in phase 2 for rare heart disease ATTR cardiomyopathy. ...

Bill Gates warns that continued U.S. cuts to global health aid could result in 8 million additional child deaths by 2040, urging Congress to reverse course and restore funding to critical programs ...